ELISA in Relapsed/Refractory MM

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least one prior line of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.

Trial Details

NCT ID
NCT06832865
Phase
PHASE2
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • elranatamab
  • Isatuximab SC
  • Isatuximab SC-OBDS
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • 1\. This study will enroll patients with relapsed and refractory multiple myeloma who have had at least 1 prior line of therapy including patients …
  • 2\. Measurable disease of multiple myeloma as defined by at least one of the following:
  • a. Serum monoclonal protein ≥ 0.5 g/dL. Patients with IgD disease and lower amounts of monoclonal protein may be permitted to enroll with PI approval
  • b. ≥ 200 mg of monoclonal protein in the urine on 24-hour electrophoresis

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →